MR Spectroscopy in Multiple Sclerosis - A New Piece of the Puzzle or Just a New Puzzle by Fahmy Aboul-Enein
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
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SMZ-Ost Donauspital, Department of Neurology 
Austria 
Systems do not exist in Nature but only in man’s minds.1 
1. Introduction 
In the late ‘80s magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS) revolutionized the care and monitoring of patients with multiple sclerosis (MS). 
For the first time detailed, high resolution images of the brain, spinal cord and lesions 
could be made by MRI in vivo, and followed over time. However, the changes detectable 
on T1- or T2-weighted magnetic resonance images are non-specific for the underlying 
pathology, especially in MS patients, and slow down the enthusiasm. They may reflect 
edema, demyelination, axonal loss, inflammation, gliosis, remyelination, or Wallerian 
degeneration in MS. 
Similar it is with MRS. Early on it was suggested that metabolites within the tissue may 
reflect certain cellular compartments and tissue conditions in health and disease. First 
reports about in vivo detection of brain metabolites in humans were published in 1989 
(Bruhn et al., 1989; Frahm et al., 1989a; 1989b). Combined with conventional MRI technique 
spatial anatomical and chemical information about the analysed tissue may be achieved. 
MRS was approved by the FDA in 1996. However, only few metabolites are detectable (table 
1), limiting the main applications of MRS yet to (1) brain tumors (low grade vs. high grade 
gliomas, metastasis, lymphoma, meningeoma), (2) follow-up of tumors (under 
chemotherapy and radiotherapy), (2) infectious, mostly focal CNS processes such as 
pyogenic abscesses, toxoplasmosis, tuberculosis, cryptococcosis, and (3) hepatic 
encephalopathy, other metabolic disorders, inborn errors of metabolism or hypoxic 
encephalopathy. In some selected MS cases MRS might be useful to differentiate tumor-like 
MS brain lesions or Balo-like MS lesions from tumor lesions (table 1) or confluent MS lesions 
from leucodystrophies or leucoencephalopathies. 
Well characterized peaks obtained at long echo times (more than TE 135ms, highlighted in 
grey) are: (1) at 2.0 ppm (‘NAA-peak’; N-acetyl-aspartate (NAA)), (2) at 3.0 ppm (‘Cr-peak’; 
creatine (Cr)), (3) at 3.2 ppm (‘Cho-peak’; choline (cho)), (4) at 1.3 ppm (‘Lac-peak’; lactate 
(Lac)), (5) at 1.48ppm (‘Alanine Peak’; alanine (Ala)),   
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marker 
(metabolite) 
ppm [mM] indicates possible to find in… 
lipids 0.9-1.2 - 
tissue necrosis 
(highly specific) 
brain tumors, abscesses, 
tissue necrosis 
cytosolic amino 
acids 
(valine, leucine, 
and iso-leucine) 
0.9 - 
products of proteolysis
(neutrophil cells) 
abscesses, 
neurocysticerkosis 
(but not in neoplasms!) 
lactate 
(Lac) 
1.2 - 
anaerobic glycolysis; 
inverted double peak 
(TE136ms) 
Balo like MS lesions, 
malignant tumors, infarcts, 
abscesses, mitochondrial 
disorders 
alanine 
(Ala) 
1.48 - 
inverted double peak 
(TE 136ms) 
meningeomas 
brain abscesses 
acetate 1.5 - 
product of propionic 
acid fermentation 
and mixed acid 
fermentation 
(anaerobic bacteria) 
abscesses, 
neurocysticercosis 
N-acetylaspartate
(NAA) 
2.0 7-17 neurons, axons 
decreased in tumors, and 
any process with tissue 
destruction 
glutamate and 
glutamine 
(glx) 
2.2-2.7
6-12 
and 
3-12 
excitatory 
neurotransmitter 
increased in stroke, 
lymphoma, hepatic 
encephalopathy, metabolic 
disorders 
succinate 2.4 - 
product of propionic 
acid fermentation 
and mixed acid 
fermentation 
abscesses, 
neurocysticercosis 
Creatine 
(Cr) 
3.0 4.5-10.5
cell energy/ 
metabolism 
mostly stable, used as 
reference peak 
Choline 
(Cho) 
3.2 0.5-3.0 
cell membranes (cell 
turnover, cell 
destruction) 
tumors, lymphomas, 
stroke, infectious 
processes, MS 
myo-Inositol 
(mIns) 
3.5 4.0-9.0 
glucose metabolism 
mainly in astrocytes 
gliosis, hepatic 
encephalopathy, pontine 
myelinolysis, MS 
Table 1. Brain metabolites 
And at short echo times (less than TE 30ms) are : (6) at 3.5 ppm (‘mIns-Peak’; myo-inositol, 
(mIns)), (7) at 0.9-1.2 ppm (‘free lipids peak’). 
Normal peak levels are given in [mM].  
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Brain metabolites were suggested as markers for (1) neurons (NAA), (2) energy metabolism 
(Cr), (3) cell membranes or cell membrane turnover (Cho), (4) anaerobic glykolysis, i.e. 
tissue necrosis (Lac, lipids, cytosolic amino acids, Ala, acetate, succinate), (5) astrogliosis 
(mIns), and (6) myelin break down (lipids, cytosolic amino acids). Abnormally strong or 
weak peaks or certain patterns of several peaks may be indicative for various pathological 
processes, and may help to interpret changes found by conventional MRI.  
For instance, lac is normally only detectable if the lac concentration in the CNS parenchyma 
has reached at least the lac concentration in the cerebrospinal fluid (CSF). Lac is the end 
product of anaerobic glycolysis and may occur in severe tissue necrosis or abscesses (table 1).  
The most discussed MRS peaks (or brain metabolites) yet are, NAA, Cho, Crea and mIns.  
1.1.1 N-acetyl-aspartate (NAA), at 2.0 ppm  
In normal CNS tissue the highest peak in the proton spectrum is found at 2.0 ppm, 
resembling the sharp resonance signal from NAA, largely composed of NAA itself, and to a 
lesser proportion out of N-acetyl-aspartate-glutamate. NAA is an amino-acid derivative 
synthesized from L-aspartate and acetyl-CoA. NAA was found to be mainly expressed in 
the mitochondria of neurons, their cell bodies, dendrites and axons, and thus was suggested 
to indicate either the structural or functional integrity of neurons or axons. However, its 
function remains unknown. In principal three scenarios, where a reduction of the NAA peak 
might occur, are discussed: (1) if neurons or axons are damaged irreversible, and 
degenerate, (2) if their density is reduced relatively in the tissue due to oedema, or (3) if 
their function is impaired, only.  
1.1.2 Choline (Cho), at 3.2 ppm 
Cho and Cho-containing phospholipids hardly resonate under normal conditions because 
they are mainly insoluble and immobile as they constitute all cell membranes and myelin. In 
tumors, inflammation, infarcts, leucoencephalopathy, leucodystrophies or in certain MS 
lesions, high cell membrane turnover due to cellular mitosis and cell death, or myelin break 
down may lead to higher concentration of soluble, freely mobile Cho, which may be 
detected at 3.2 ppm on the frequency scale. If freely mobile Cho molecules are abundant and 
resonate, an increased ‘Cho-peak’ may be found.  
Note that severe tissue destruction, i.e. necrosis, where cell membranes are heavily 
damaged, torn asunder and single cell membrane compounds released into the necrosis, 
may produce other resonances or peaks (such as free lipids, lac, acetate, succinate). 
1.1.3 Creatine (Cr), at 3.0 ppm 
The ‘Cr-peak’ is composed of Cr and phosphor-creatine, and lies at 3.0 ppm on the 
frequency scale, representing a marker for cellular energy metabolism. As the Cr 
concentration was found relatively stable throughout the CNS, and found relatively 
resistant to change, Cr is often used as internal standard, and thus the signals strength of the 
other metabolites are expressed as ratio to Cr. However, under certain conditions such as 
higher age, tumors, infarcts or trauma Cr is found decreased. (Sometimes Cr was also found 
increased in the NAWM of MS patients, see below). 
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1.1.4 Myo-Inositol (mINS), at 3.5 ppm 
The ‘mIns-peak’ is believed to resemble an ‘activated’ state of higher cell metabolism or 
proliferation of astrocytes. mIns is a sugar-like molecule which may be crucial for the 
osmotic regulation in the CNS parenchyma. An elevated ‘mIns-peak’ may be interpreted as 
higher astroglial activity and proliferation or gliosis.   
But MRS allows a limited view only. From a scientific point of view, it is hardly conceivable 
that a few metabolites really allow the complete representation of complex biological 
processes of individual cells within the spectroscopied CNS tissue. Note that the function of 
the metabolites and that their (resonance) characteristics under certain conditions are still 
largely unknown. 
One of the most important and controversially discussed hypotheses today is that ‘early 
axonal damage already exists in very early stages of (all) MS patients’. This view may open 
the way for ‘an (very) early treatment’ of MS patients, also if clinical symptoms are minor or 
even absent (Miller et al., 2008; Gilmore et al., 2010). This hypothesis comes mainly from 
MRI and MRS findings reporting reduced NAA levels in the normal appearing white matter 
(NAWM). NAA levels are suggested as marker for neuronal integrity and function and 
should reflect the burden of disease in MS patients (figure 1). 
 
 
 
Fig. 1. A hypothesis, nothing else. a, It remains unclear, simply hypothetically, whether 
progressive, i.e. steadily ongoing ‘silent’,  axonal damage exists in all MS patients, or not 
and if so, whether it can be reliable detected and monitored over time. It was suggested that 
NAA levels in the NAWM decline in some MS patients continuously. This NAA decline 
would be expected more than naturally occurring declines by age. b, Objective and neutral 
interpretation of the data allows also a second scenario, where brain volume (and NAA 
concentration?) only slightly decreases with age, or secondary progression. And during 
relapses temporarily a decrease of NAA can be found, that may recover fully.  
However, due to the most often relapsing-remitting course of MS patients, with remission 
over years and sometimes over decades, early treatment per se must be carefully considered 
and risks and benefits carefully weighed.    
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In biological sciences, the role of a method is even more important than in other sciences, 
 because of the immense complexity of the phenomena and the countless sources of error,  
which complexity brings into experimentation.2 
1.2 Recently the pivotal role of advanced MR technique was emphasized 
1.2.1 ‘Differential diagnosis of suspected multiple sclerosis: A consensus approach’ 
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, 
Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, 
Panitch H, Richert JR, Reingold SC, Polman CH.  
Multiple Sclerosis, Vol. 14, No. 9, pp. 1157-1174. 
P 1164, […] Although symptoms and signs of a monophasic illness have been an essential 
prerequisite for diagnosis of CIS, there is an exceptional scenario that the Panel feels warrants 
inclusion as CIS Type 5 (Table 2): patients who have no symptoms or only non-specific symptoms 
(e.g., headache, dizziness), but have MRI evidence for multifocal abnormalities typical for 
demyelination. Such patients are increasingly identified using MRI for incidental indications (e.g., 
headache) especially with high-field strength magnets with greater sensitivity for such lesions [17]. 
Current criteria preclude a diagnosis of MS without objective clinical evidence for CNS abnormality 
and the ability to establish a confident diagnosis of MS in such individuals and their natural history 
should be addressed through prospective studies [18]. […] 
P 1172, […] Disease biomarkers will aid enormously in differential diagnosis. Accurate and sensitive 
disease markers – imaging or laboratory based – may provide non-invasive aids to differential 
diagnosis. The discovery of NMO-IgG that helps to distinguish NMO from MS is a good example. 
Relevant imaging advances may include non-conventional MR techniques to quantitate change in 
normal appearing white matter that may be relatively specific for MS, and high-field MRI to better 
visualize Dawson’s fingers [17] or cortical lesions that may be specific to MS. […] 
Interestingly, the reference No. 17 (title ‘Cerebral Cortical Lesions in Multiple Sclerosis 
Detected by MR Imaging at 8 Tesla’) is a case report where the post mortem/ex vivo findings 
of a single patient, a male aged 42 years, were described (Kangarlu et al., 2007). Coronal 
slices of the patient’s formalin fixed brain were examined using MRI at 8T. Details about the 
disease course, or how the diagnosis ‘MS’ were made was not specified, p262, […] 
‘Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla.’ 
Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. 
AJNR American Journal of Neuroradiology, Vol. 28, No. 2, pp. 262-266. 
A 42-year-old man with severe disabilities secondary to MS died of aspiration pneumonia. In the 
year before his death, he had been seen at our medical center on 2 occasions, mostly for palliative 
care. He was bed-bound and very dependent for all activities of daily living. He was paraplegic 
with additional severe weakness of the upper extremities, which were also severely ataxic. The 
ataxia also affected his trunk and prevented him from sitting unassisted in a standard wheelchair. 
He had complete bilateral internuclear ophthalmoplegia, vertical nystagmus, and severe 
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titubation of his head. His ability to communicate was intact, though his speech was barely 
intelligible. His mentation seemed intact; he remained completely oriented and participated in all 
decisions of his care, including his desire to have his brain evaluated for scientific endeavors after 
death. He needed to be fed through a percutaneous gastrostomy tube. Cognitive status could not 
be formally evaluated because of the severity of his disabilities. The duration of his disease was 
estimated to be approximately 12 years. At the time of his demise, he was considered to be in the 
advanced stages of the secondary-progressive form of MS. His general health was otherwise 
excellent, and he had no known cardiovascular, cerebrovascular, hypertensive, or diabetes-related 
disabilities. […]. 
[…] 
For reference No. 18 see, Lebrun at al., 2008 and the comment by Chattaway, 2008. 
[…] 
As critical readers we are aware that we must read more than the headlines and abstracts 
of the papers and that the hypothesis that ‘early axonal damage already exists in very 
early stages of (all) MS patients’ has yet to be proven (Figure 1), and that the very 
controversial discussion is still ongoing (e.g. Chattaway, 2008 and 2010; Gilmore et al., 
2010; Lebrun et al., 2008; Miller et al., 2008). In any case, we must keep in mind that direct 
scientific evidence is still lacking.  
I consider the hospital as the antechamber of medicine. 
It is the first place where the physician makes his observations. 
But the laboratory is the temple of the science of medicine.3 
2. Multiple sclerosis  
Multiple sclerosis (MS) is a chronic idiopathic disease of the central nervous system (CNS). 
Inflammation, demyelination and axonal injury are most typical pathological features, but 
their underlying pathogenetic mechanisms are still unclear (Barnett et al., 2009; Hibberd, 
1994; Lassmann et al., 2007). They are probably complex and heterogeneous, and may be 
triggered outside the CNS or conversely, may be triggered within the CNS. And they may 
initiate focally and further disperse, or they may affect the whole CNS diffusely at once. In 
either case, blood brain barrier (BBB) alterations are conceivable, focally or diffusely, visible 
or invisible (Figure 2). But at least the primary cause of MS, and whether BBB alterations are 
the initial detectable pathological event in the evolution of the MS lesions, or why and 
whatever, the MS lesions are caused by, remains unknown (Aboul-Enein & Lassmann, 2006; 
Allen & McKeown, 1979; Allen et al., 1989; Barnes et al., 1991; Barnett et al., 2004; Barnett & 
Prineas, 2009; Henderson et al., 2009; Höftberger et al., 2004; Lassmann et al., 2007). 
If an idea presents itself to us, we must not reject it simply,  
because it does not agree with the logical deductions of a reigning theory.4 
It is what we know already that often prevents us from learning.5 
                                                 
3 Claude Bernard (French physiologist, 1813 – 1878) 
4 Claude Bernard (French physiologist, 1813 – 1878) 
5 Claude Bernard (French physiologist, 1813 – 1878) 
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Fig. 2. ‘The chicken or the egg causality dilemma’ in MS lesion evolution. 
Red, enhancing (active) MR lesions; blue, old(er), at least not enhancing lesions; green, in 
MR invisible inflammation or an underlying, yet not determined, pathogenetic mechanism 
around focal MS lesions; lime, hypothesized invisible, yet not determined, 
compartmentalized focal or diffuse inflammation or yet not determined pathogenetic 
process.  a-e, the disease might be triggered from outside the CNS. a, normal brain without 
any lesion or invisible disease activity; b, the naïve brain with two enhancing lesions (red) 
only; c, brain with typical periventricular and subcortical old (not enhancing) white matter 
(WM) lesions only; d, same scenario as in c, but with new enhancing lesions (red). e, older 
non enhancing WM lesions (blue) of which one enhances in its right anterior margin (red 
margin) with ongoing (invisible) activity (green) beyond the in MR visible lesion border and 
two new enhancing (red) with invisible activity in the left hemisphere. f-o, the disease 
might be already compartmentalized within the CNS from the very beginning, but 
invisible with MRI (lime):  f-j, focally, but widely dispersed; k-o, diffusely within the CNS. 
f-o, show the same enhancing (red) and old/er (blue) in MRI detectable lesions as presented 
in a-d. In both scenarios, the in MRI detectable lesions may resemble only the ‘tip of the 
iceberg’, leading to over time and space disseminated focal lesions with BBB alterations. In 
other words, the hypothesized underlying, invisible disease activity may lead from inside 
out to focal ‘eruptions’ with BBB alterations and influx of inflammation, or might attract 
inflammatory cells which lead to the BBB breakdown. The infiltrating inflammatory cells 
might be primarily harmful to the CNS, or otherwise, they might be primarily beneficial but 
may cause substantial bystander tissue damage, or both. 
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2.1 Diagnostic criteria and the disease course of MS 
The diagnosis ‘MS’ is a clinical one, if stringent diagnostic criteria are fulfilled and if there is 
no better explanation for the clinical presentation (Mc Donald et al., 2001; Polman et al. 2005, 
2010; Poser et al., 1983; Schuhmacher et al., 1965). The diagnosis ‘MS’ is based on the clinical 
evidence for typical disseminated CNS lesions, and may be supported by cerebrospinal fluid 
(CSF) analysis, magnetic resonance imaging (MRI), and evoked potentials. However, all 
findings are non-specific by themselves, but overall, they might be typical for the diagnosis 
‘MS’. Up till now, a reliable specific para-clinical marker neither for the diagnosis nor for 
monitoring disease activity of MS could yet be established (e.g. Aboul-Enein et al., 2010; 
Gilmore et al., 2010; Kuhle et al., 2007; Serbecic et al., 2010, 2011). 
In most of the cases MS starts between the age of 20 to 40 years and follows a relapsing-
remitting course with clear defined relapses with no apparent clinical deterioration between 
the relapses. Each MS patient follows his/her individual disease course (Gilmore et al., 
2010). It is unclear why MS sometimes follows a benign disease course with clinical 
remission over decades, or changes after an uncertain period of time into secondary 
progression with or without superimposed relapses (SPMS, secondary progressive MS), or 
follows rarely a progressive disease course right from the disease onset (PPMS, primary 
progressive MS) (Lublin & Reingold, 1996).  
To sum up, no clinical or paraclinical parameter could yet be found, which allows a reliable 
prognosis of the ‘relapse-free intervals’, the relapses, the sequelae and the possible 
‘conversion into secondary progression’. In particular, neither the frequency nor severity of 
relapses nor disability in the first years after onset nor the lesion load in magnetic resonance 
images (MRI) correlates strictly with the disease activity or its impact on the individual 
clinical disease course (e.g. Brex et al., 2002; Fisniku et al., 2008; Gilmore et al., 2010; 
Weinshenker et al., 1989a, 1989b). And axonal alterations or axonal loss, which is yet 
suggested as main pathological substrate, unfortunately, provides only some explanation. 
In teaching man, experimental science results in lessening his pride more and more by  
proving to him every day that primary causes, like the objective reality of things,  
will be hidden from him forever and that he can only know relations.6 
2.2 The clinical-pathological paradox of MS 
Pathologists and neurologists have known for a long time that a considerable amount of 
CNS lesions with demyelination, axonal changes, inflammation and gliosis might be found, 
although clinical signs and symptoms were absent or should have never occurred 
(Lumdsen, 1970). A plausible explanation could be that in such cases the lesions were small, 
or that they occurred in non-eloquent CNS areas, but in any way, it means that recovery of 
function is possible. Axonal loss of function may be caused either by structural damage such 
as demyelination and (secondary) axonal injury (McDonald and Sears, 1970) or may be 
caused without any detectable structural damage by certain immune mediators only, which 
might interfere with axonal conductance (Aboul-Enein et al., 2006; Smith & Lassmann, 2002). 
Block of conduction is in principal reversible as axons may be remyelinated and the axonal 
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sodium channels may be restored, or the conduction block causing mediators may be removed 
(Smith, 2007). Of course, other mediators derived from any other tissue or incorporated from 
outside, and being not associated with the body’s immune system might be worth considering. 
But neither remyelination nor gliosis, both can be extensive in autopsies, correlate to 
permanent functional loss, if at all, only the irreversible axonal loss was found to correlate. 
And pathologists have only a very limited point of view (as neurologists and radiologists, 
too!). They can merely try to reconstruct the in vivo situation in most of the cases after long 
disease courses with very specific markers which however, allow mostly no further statement 
about the in vivo integrity and function over the patients’ lifetime.  
2.3 The clinical-radiological paradox of MS 
On a more philosophical - someone might argue - on a very ‘realistic’ level, we must 
remember that we merely know nothing about the disease’s origin or the disease’s specific 
processes. Direct scientific evidence is lacking for almost every little so far identified 
experimental, pathological, clinical, radiological or epidemiological fragment. We even do 
not know whether MS is one disease or a whole spectrum of disorders, or vice versa, 
whether the same pathogenetic mechanisms may have different effects in different 
individuals, or at different times in one individual MS patient. Otherwise not a specific 
primary cause itself, but the lack of specific resistant factor(s) or repair mechanisms might 
be responsible that some individuals become ill (and diagnosed), whereas all the others 
remain healthy. In other words, how many healthy people (Also you, dear readers!) could 
have a considerable lesion load or brain atrophy in MRI suggestive for MS, but without 
any further consequence as they feel healthy (and never see a doctor). Patients diagnosed 
with MS may be that ones with lesions mainly in eloquent areas. Thus they may resemble 
only a very small portion, the so called ‘tip of the iceberg’, but of course, they shape our 
view about MS.  
However, by occasion some patients, who receive a MRI of their brain (because of a wide 
range of ‘unspecific’ symptoms, and because MRI is now widely available), show 
asymptomatic lesions suggestive for MS (Chataway, 2010). Recently, these ‘patients’ were 
classified as radiological isolated syndrome (RIS) or clinical isolated syndrome (CIS) type 5 
(Miller et al., 2008). It is controversially discussed, whether these ‘patients’ should be 
followed closely, or even treated (Chataway, 2008, 2010; Gilmore et al., 2010; Lebrun et al., 
2008; Miller et al., 2008; Sellner et al., 2010; Siva et al., 2009).  
The link between disease onset and possible irreversible end-stage parameters such as glial 
scar tissue formation and brain and spinal cord atrophy is still missing. MRI and magnetic 
resonance spectroscopy (MRS) allows to visualize changes during individual disease 
courses in vivo, but they provide at least information from magnetic fields of certain 
molecules, mostly hydrogen nuclei (protons, or 1H) of water molecules, nothing else. 
A fact in itself is nothing.  
It is valuable only for the idea attached to it,  
or  for the proof which it furnishes.7 
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3. Of what we believe about MRI lesion evolution 
3.1 Acute enhancing lesions 
It is believed, that the alteration of the BBB may be the earliest event in formation of a focal 
MS lesion which may be visualized by gadolinium enhancement in T1-weighted MRI 
images with high sensitivity. Prerequisite for this is that gadolinium must be able to reach 
the specific region and that the BBB alterations are rather gross (‘BBB leakage’, in a strict 
sense). Gadolinium enhancement was suggested to be more sensitive in detecting disease 
activity than either clinical examination or T2 weighted MRI (Miller et al., 1993). 
Theoretically, all relapses should be accompanied by new, active enhancing MRI lesions 
(Figure 1b, d, e g, i, j, l, n o). But, enhancement is dependent on the dose and the technique 
used, and dependent on the lesion size and location. This must be borne in mind when 
different studies are compared.  
Higher doses of gadolinium (triple dose, 0.3mmol/kg body weight), longer delay between 
injection and the MRI scan (30-60 minutes), and the combination with a magnetization 
transfer pulse which suppresses the normal brain tissue, but spares areas with enhancement, 
can increase the sensitivity of MRI, i.e. make an higher number of enhancing MS lesions 
visualized (Filippi et al., 1996; Miller et al., 1998). Caveat is the increase of false positive 
results. However it remains unclear, if all lesions, in particular, those with only subtle BBB 
alterations can be detected hereby (Barnes et al., 1991; Kwon & Prineas et al., 1994, Waubant, 
2006). Very often neurological symptoms may occur without any (correlating) acute 
enhancing MRI lesions, especially in the spinal cord. And most confusing is that acute 
enhancing MRI lesions that are clinically silent, may be found between relapses, even 
though they are located in eloquent areas (Davie et al., 1994; Schubert et al., 2002). 
Put off your imagination as you take off your overcoat,  
when you enter the laboratory.8 
In contrast to usual CNS immune surveillance with regular, always occurring 
transmigration of only few immune cells (Aboul-Enein et al., 2004), it is supposed that the 
lesion evolution starts with large numbers of immune cells that cross the BBB into the CNS 
parenchyma, and thus may lead to BBB leakage (Barnes et al., 1991; Hawkins et al., 1991). 
This is mainly supported by animal models of experimental autoimmune encephalomyelitis 
(EAE) that however, must not be uncritically translated to humans. In EAE huge masses of 
CNS antigen specific immune cells or antibodies, or both, are injected, and initiate an acute, 
but mostly monophasic inflammatory disease in the CNS (Flugel et al., 2001, 2007; Floris et 
al., 2004; Hawkins et al., 1991; Kawakami et al., 2005). The situation in humans with MS 
remains unclear. It is even unknown whether the inflammation is primary, whether the 
infiltrating immune cells themselves cause the tissue damage, or whether some other 
primary event within the CNS leads to the actual lesion formation and attracts the 
inflammatory cells into the CNS. The inflammation may be beneficial or conversely, may 
cause some bystander damage (Barnett & Prineas, 2004; Henderson et al., 2009; Hohlfeld et 
al., 2006). Anyway, corticosteroids may decrease or may completely suppress the 
enhancement of MS lesions for several weeks (Barkhof et al., 1991, 1994; Burnham et al., 
1991). Conceivable are various mechanisms of action such as apoptosis of circulating 
                                                 
8 Claude Bernard (French physiologist, 1813 – 1878) 
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immune cells, down-regulation of adhesion molecules on immune cells or endothelial cells, 
or both, or another yet not determined mechanism, that seals the BBB (Engelhardt, 2006; 
Gelati et al., 2002; Leussink et al., 2001; Prat et al., 2002). 
3.2 Others than acute enhancing lesions 
Most of the acute gadolinium enhancing MS lesions change their MR characteristics in 
further follow up. Some convert to mildly or severly hpointense T1 lesions which might 
reflect severe underlying tissue damage with marked axonal loss and correlating reduced 
NAA levels (e.g. van Walderveen et al., 1998), others convert to persistent T2 lesions after 
several months. The latter may appear hyperintense in T1 weighted images or become 
undectable in T1 weighted images. In persistent T2 lesions, no matter what behavior they 
had in T1, nearly all thinkable metabolite constellations were described (increase, decrease, 
no changes of NAA, Cr, Cho, mIns etc., e.g. Davie et al., 1997; van Walderveen et al., 1997.). 
Reduced NAA levels might reflect axonal injury, dysfunction or loss. They might be 
temporarily or permanently, within lesions or remote from lesions due to secondary axonal 
degeneration or Wallerian degeneration. (Increased NAA levels have yet been described in 
Canavan’s disease only). Elevated Cr, mIns levels were suggested to reflect ‘higher 
metabolism’ in astrocytes, and increased Cho was suggested to reflect higher cell membrane 
turnover or proliferation of astrocytes within MS lesions or NAWM. Decreased levels might 
be due to decreased cell numbers or lower ‘cellular energy state’. These divergent results 
may be explained by the very small and heterogeneous patient cohorts (e.g. 2 RRMS and 12 
SPMS aged from 28 to 61 years, and 4 controls aged 33 to 48 years in van Walderveen et al., 
1999), by the use of a 1.5 Tesla 1H-MRS and by the measurement of metabolite ratios instead 
of absolute metabolite concentrations.    
Only single reports of histopathological correlations to in vivo MR data have been published 
(Bitsch et al., 1997) that are of most importance for our understanding, but must be 
interpreted very carefully. Biopsies are only very seldom performed in MS patients, mostly 
if tumor lesions must be ruled out or verified. Whether demyelinating tumor-like MS lesions 
have the same characteristics and behavior like common unspecific smaller MS lesions, is 
unclear. Moreover, it is still unknown, if MS is one disease or a syndrome of many 
disorders, or if the same trigger causes the same pathological changes in different MS 
patients or if the same trigger at different time points leads to different types of lesions in 
one individual MS patient. Therefore, any general interpretation must be done with caution.     
Men who have excessive faith in their theories or ideas 
are not only ill prepared for making discoveries.  
They also make very poor observations.9 
4. Of what we believe to see with MRT and MRS 
MRI allows the detailed visualization of the anatomical and pathological structures based on 
different signals of freely mobile hydrogen protons between different tissues or anatomical 
compartments.  
                                                 
9 Claude Bernard (French physiologist, 1813 – 1878) 
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The signals from freely mobile hydrogen protons are up to 1000 fold more than the 
resonances from other brain metabolites. The selective suppression of the signal from 
hydrogen protons ‘unmasks’ the spectra of various specific metabolites within the magnetic 
resonance frequency spectrum, and thus allows to detect and separate them, as each brain 
metabolite resonates at a characteristic position along the frequency scale expressed in parts 
per million (ppm). The sharpness and the amplitude of a specific peak along the frequency 
scale is determined by the specific metabolite itself, its concentration and most importantly, 
by its mobility. The brain metabolites must be freely mobile to produce well detectable 
peaks. In general, the more freely mobile specific metabolites in a specific volume of interest 
(VOI) resonate the higher their resulting peak is. If the specific peak is low, or even absent, 
this could mean that the protons in the examined VOI are either not occurring or not freely 
mobile or might require specific MR technique/parameters to be detected. 
For instance, lipids are abundant within the brain, but under normal conditions immobile, 
as they constitute mainly highly compacted myelin. If myelin breaks down, they become 
mobile and may produce a ‘free lipid peak’ in the frequency spectrum at 0.9-1.2 ppm.  
‘NAA-peak’ reduction or reduction of NAA absolute concentration in the spectroscopied 
tissue may occur due to axonal injury, damage or even loss, and might be irreversible or 
reversible. Infarcts, tumors, traumatic injury may lead to severe tissue destruction, heavy 
axonal damage and loss of axons, and thus may lead to irreversible NAA reduction. In the 
case of temporarily NAA reduction, various scenarios are conceivable: firstly, the NAA 
reduction correlates with structural axonal damage, i.e. axonal loss that in principle may be 
restored by remyelination and regain more or less the same NAA concentrations as before. 
Secondly, NAA reduction might reflect mitochondrial dysfunction in neurons or axons, 
whatever the underlying cause might be (e.g. inflammatory mediators, or any other 
molecule which might interfere with mitochondrial function), and might be restored when 
the interfering stimulus or agent is removed. The numbers of axons can be unchanged, or 
can be markedly reduced but have the same NAA levels, i.e. more ‘active mitochondria’ per 
axon or neuron. In other words, the loss of axons might be compensated with increase of 
numbers of mitochondria or increase of the NAA content in axonal mitochondria. (It was 
suggested that NAA might play a crucial role in the mitochondrial function).    
A tumor or tumor-like brain lesion may either show profound reduction of NAA and 
relative high Cr concentrations in a first baseline scan. Several weeks later the NAA levels 
might be found still reduced or restored. In the first case, a tumor must be considered, 
whereas in the latter case a demyelinating tumor-like lesion with subsequent remyelination 
seems conceivable. (Tumors do not recover spontaneously).     
A discovery is generally an unforeseen relation not included in theory, 
for otherwise it would be foreseen.10 
5. Of what could be found with MRS in early stages of RRMS or even in CIS 
Medline Database Research using following search term/key words {"multiple sclerosis" 
AND (NAWM OR "normal appearing white matter") AND ("N-acetyl-aspartate" OR NAA) 
and ("spectroscopy") and "absolute concentration"} yielded 67 results (until March 2011).  
                                                 
10 Claude Bernard (French physiologist, 1813 – 1878) 
www.intechopen.com
 MR Spectroscopy in Multiple Sclerosis - A New Piece of the Puzzle or Just a New Puzzle 
 
59 
Only 38 original articles providing MRS data (NAA/Cr ratios and/or NAA absolute 
concentrations) of RRMS or CIS patients could be further analysed. Other search results had 
to be excluded because they included MRS studies on SPMS or PPMS patients only (Leary et 
al., 1999; Cucurella et al., 2000; Sastre-Garriga et al., 2005), or did not compare the NAWM of 
matched controls (Hiehle et al., 1994), or were reviews, post mortem studies, MRS studies on 
patients with neuromyelitis optica, systemic lupus erythematodes or relatives of MS patients 
who were not afflicted with MS. 
A meta-analysis of the remaining 38 identified MRS studies could not be performed as they 
differ from study design (inclusion criteria and technical parameters), and do not provide all 
necessary data such as detailed demographic data and individual values for metabolite 
ratios and concentrations. However, following characteristics of the NAWM of CIS and 
RRMS patients could be identified (table 2, references are listed chronologically by 
publication date).  
 
 
 
 
Table 2. Synopsis of literature research. 
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5.1 Reported NAA changes 
5.1.1 Decreased NAA ratios or NAA concentrations  
Twenty-four MRS studies were published with decreased ratios of NAA to Cr or Cho, or 
decreased NAA absolute concentrations in the NAWM in a total of  56 CIS or 418 RRMS 
patients (Davie et al., 1994; Husted et al., 1994; Peters et al., 1995; Fu et al., 1998; Schiepers et 
al., 1997; Foong J et al., 1999; Sarchielli et al., 1999; van Walderveen et al., 1999; Suhy et al., 
2000; de Stefano et al., 2001; Tedeschi et al., 2001; Kapeller et al., 2001; Chard et al., 2002; de 
Stefano et al., 2002; Casanova et al. 2003; Inglese et al., 2004; Adalsteinsson et al., 2004; He et 
al., 2005; Staffen et al., 2005; Tiberio et al., 2006; Sijens et al., 2006; Pascual et al., 2007; Wattjes 
et al., 2008; Wattjes et al., 2008). 
5.1.2 No significant changes of NAA ratios or NAA concentrations 
Fourteen MRS studies were published with no significant NAA changes in the NAWM in a 
total of  184 CIS or 263 RRMS patients (Davie et al., 1997; Sarchielli et al., 1998; Brex et al., 
1999; Kapeller et al., 2002; Fernando et al., 2004; Ruiz-Pena et al., 2004; Vrenken et al., 2005; 
Mathiesen et al., 2005; Srinivasan et al., 2005; Khan et al., 2005; Khan et al., 2008; Kirov et al., 
2008; Bellmann-Strobl et al., 2009; Aboul-Enein et al., 2010). 
5.2 Reported Cho changes 
5.2.1 No significant changes of Cho ratios or Cho concentrations  
Twenty-nine MRS studies were published with no significant Cho changes in the NAWM 
in a total of  190 CIS or 513 RRMS patients (Husted et al., 1994; Peters et al., 1995; Schiepers 
et al., 1997;Davie et al., 1997; Sarchielli et al., 1999; Foong J et al., 1999; Sarchielli et al., 1999; 
Brex et al., 1999; van Walderveen et al., 1999; Suhy et al., 2000; de Stefano et al., 2001; 
Kapeller et al., 2001; Chard et al., 2002; de Stefano et al., 2002; Kapeller et al., 2002; Casanova 
et al. 2003; Inglese et al., 2004; Adalsteinsson et al., 2004; Fernando et al., 2004; Ruiz-Pena et 
al., 2004; Vrenken et al., 2005; Mathiesen et al., 2005; Khan et al., 2005; Sijens et al., 2006; 
Wattjes et al., 2008; Wattjes et al., 2008; Khan et al., 2008; Bellmann-Strobl et al., 2009; Aboul-
Enein et al., 2010).  
5.2.2 Significant changes of Cho ratios or Cho concentrations 
In two MRS studies (8 and 19 RRMS patients) Cho was found decreased (Davie et al., 
1994; Tedeschi et al., 2001) and in 4 MRS studies (9, 16, 43 and 21 RRMS patients) Cho 
levels were found increased (He et al., 2005; Srinivasan et al., 2005; Pascual et al., 2007; 
Kirov et al., 2008). 
5.3 Reported mIns changes 
5.3.1 No significant changes of mIns ratios or mIns concentrations 
Five out of 12 MRS studies reported no significant mINS changes in the NAWM of in a total 
of 76 CIS or 17 RRMS patients (Brex et al., 1999; Sarchielli et al., 1998; Sijens et al., 2006; 
Wattjes et al., 2008a; Wattjes et al., 2008b). 
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5.3.2 Significant changes of mIns ratios or mIns concentrations  
Seven out of 12 MRS studies reported increased levels of mIns in the NAWM of in a total of 
96 CIS or 116 RRMS patients (Kapeller et al., 2001; Chard et al., 2002; Fernando et al., 2004; 
He et al., 2005; Vrenken et al., 2005; Srinivasan et al., 2005; Kirov et al., 2008).  
Keep in mind, that in most of the cases statistical characteristics of groups of MS patients 
were reported. Only very rarely the presentation of the data allow the readers their own 
interpretation because data are summarized in tables (with means, standard errors or 
standard deviations, range) and bar charts, instead of tables and scatter plots presenting all 
data for each individual patients. That groups of patients differ significantly, does not 
necessarily mean that all patients differ significantly from age and sex matched normal 
controls. They even may lie within normal range. For instance, the NAA levels of RRMS 
patients and even a proportion of SPMS patients were found within the range of NAA 
absolute concentrations that were found in healthy controls (Aboul-Enein et al., 2010; fig.3 
squares, RRMS patients (n=27); circles, SPMS patients (n=10); triangles, controls (n=8); bars, 
means). However the mean NAA levels of SPMS patients were found significantly 
decreased compared to controls and RRMS patients.   
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Fig. 3. MRS absolute concentrations of brain metabolites in the NAWM of MS patients and 
controls (from Aboul-Enein F et al., 2010). White, NAA [mM];  grey, Cr [mM]; black, Cho [mM].  
6. Conclusion  
Currently the potpourri of data allows no reliable general information or even evidence 
about metabolite changes in the NAWM that were hypothesized to occur in all CIS or RRMS 
patients. Sophisticated meta-analysis is yet not possible as different MR methods were used, 
and individual data such as age, sex, disease duration, disease activity, lesion load, therapy, 
and metabolites concentrations cannot be extracted. Moreover, it remains unclear, what the 
specific metabolites reflect in the tissue of individual MS patients. In any case, we must be 
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aware that the magnetic resonances of freely mobile hydrogen protons or certain other 
freely mobile metabolites are converted to images, and thus ‘are made visible for the 
human’s eye’.     
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